BCA
SYRE icon

Berman Capital Advisors’s Spyre Therapeutics SYRE Stock Holding History

Berman Capital Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Buy
+2
New +$350 ﹤0.01% 2219
2020
Q3 		– Sell
-24
Closed -$5K – 1766
2020
Q2 		$5K Buy
+24
New +$4.57K ﹤0.01% 997

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Berman Capital Advisors's SYRE Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Spyre Therapeutics (SYRE) in Q3 2021: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2219 among its holdings. This is a return to the name: Berman Capital Advisors previously reported a position in SYRE as recently as Q2 2020.

Berman Capital Advisors first reported a position in SYRE in Q2 2020 and has held it in 2 quarters since. The position peaked at $5K in Q2 2020. 77 funds tracked by Wall St. Rank hold SYRE as of Q3 2021.

  • Berman Capital Advisors held 2 shares of Spyre Therapeutics worth $0 as of Q3 2021.
  • Spyre Therapeutics was a new Berman Capital Advisors position in Q3 2021.
  • Spyre Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2219 holding.
  • Berman Capital Advisors first reported a position in Spyre Therapeutics in Q2 2020 and has held it in 2 quarters since.
  • Berman Capital Advisors's Spyre Therapeutics position peaked at $5K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.